Major US managers of drug benefits would continue covering Novo Nordisk A/S’s blockbuster drugs Ozempic and Wegovy if the company decides to cut their list prices, Senator Bernie Sanders said in a hearing where Novo Chief Executive Officer Lars Fruergaard Jorgensen will answer questions on the popular drugs’ costs.
“I am delighted to announce today that I have received commitments in writing from all the major PBMs that if Novo Nordisk substantially reduces the list price for Ozempic and Wegovy, they would not limit coverage,” Sanders said in a Senate Health, Education, Labor and Pensions committee hearing Tuesday.